These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 37207363)

  • 1. Degradation of Rat Sarcoma Proteins Targeting the Post-Translational Prenyl Modifications via Cascade Azidation/Fluorination and Click Reaction.
    Zhou H; Gan Y; Li Y; Chen X; Guo Y; Wang R
    J Med Chem; 2023 Jun; 66(11):7243-7252. PubMed ID: 37207363
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sequential Azidation/Azolation of Prenylated Derivatives and a Click Reaction Enable Selective Labeling and Degradation of RAS Protein.
    Gan Y; Chen X; Li Y; Guo Y; Wang R
    J Org Chem; 2023 Aug; 88(15):10836-10843. PubMed ID: 37462271
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Nitroso-Based Probes for Labeling and Regulation of RAS Proteins in Cancer Cells via Sequential Ene-Ligation and Oxime Condensation.
    Li Y; Zhou H; Liu H; Gan Y; Zheng Y; Sheng J; Wang R
    J Org Chem; 2023 Feb; 88(3):1762-1771. PubMed ID: 36691112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted i
    Guo Y; Chen X; Gan Y; Li Y; Wang R
    Bioorg Med Chem Lett; 2024 Aug; 108():129815. PubMed ID: 38795737
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting Endogenous K-RAS for Degradation through the Affinity-Directed Protein Missile System.
    Röth S; Macartney TJ; Konopacka A; Chan KH; Zhou H; Queisser MA; Sapkota GP
    Cell Chem Biol; 2020 Sep; 27(9):1151-1163.e6. PubMed ID: 32668202
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PROTAC-DB 2.0: an updated database of PROTACs.
    Weng G; Cai X; Cao D; Du H; Shen C; Deng Y; He Q; Yang B; Li D; Hou T
    Nucleic Acids Res; 2023 Jan; 51(D1):D1367-D1372. PubMed ID: 36300631
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective degradation of EGFR
    Qu X; Liu H; Song X; Sun N; Zhong H; Qiu X; Yang X; Jiang B
    Eur J Med Chem; 2021 Jun; 218():113328. PubMed ID: 33773286
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Induced degradation of proteins by PROTACs and other strategies: towards promising drugs].
    Reboud-Ravaux M
    Biol Aujourdhui; 2021; 215(1-2):25-43. PubMed ID: 34397373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cell-permeable CaaX-peptides affect K-Ras downstream signaling and promote cell death in cancer cells.
    Klimpel A; Stillger K; Wiederstein JL; Krüger M; Neundorf I
    FEBS J; 2021 May; 288(9):2911-2929. PubMed ID: 33112492
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rational Design for Nitroreductase (NTR)-Responsive Proteolysis Targeting Chimeras (PROTACs) Selectively Targeting Tumor Tissues.
    Shi S; Du Y; Zou Y; Niu J; Cai Z; Wang X; Qiu F; Ding Y; Yang G; Wu Y; Xu Y; Zhu Q
    J Med Chem; 2022 Mar; 65(6):5057-5071. PubMed ID: 35175763
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Research Progress of Proteolysis Targeting Chimeria in NSCLC Therapy].
    Jiang L; Zhang J; Hu J; Qi H; Xu H
    Zhongguo Fei Ai Za Zhi; 2022 Jul; 25(7):477-481. PubMed ID: 35899444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression.
    Wang K; Dai X; Yu A; Feng C; Liu K; Huang L
    J Exp Clin Cancer Res; 2022 Sep; 41(1):289. PubMed ID: 36171633
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineered bioorthogonal POLY-PROTAC nanoparticles for tumour-specific protein degradation and precise cancer therapy.
    Gao J; Hou B; Zhu Q; Yang L; Jiang X; Zou Z; Li X; Xu T; Zheng M; Chen YH; Xu Z; Xu H; Yu H
    Nat Commun; 2022 Jul; 13(1):4318. PubMed ID: 35882867
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design, synthesis and biological evaluation of KRAS
    Zhang X; Zhao T; Sun M; Li P; Lai M; Xie L; Chen J; Ding J; Xie H; Zhou J; Zhang H
    Bioorg Med Chem; 2023 Jan; 78():117153. PubMed ID: 36621179
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Proteolysis targeting chimeras (PROTACs) are emerging therapeutics for hematologic malignancies.
    He Y; Khan S; Huo Z; Lv D; Zhang X; Liu X; Yuan Y; Hromas R; Xu M; Zheng G; Zhou D
    J Hematol Oncol; 2020 Jul; 13(1):103. PubMed ID: 32718354
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Design, Synthesis, and Biological Evaluation of Proteolysis Targeting Chimeras (PROTACs) for the Dual Degradation of IGF-1R and Src.
    Manda S; Lee NK; Oh DC; Lee J
    Molecules; 2020 Apr; 25(8):. PubMed ID: 32340152
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Proteolysis-targeting chimeras: A promising technique in cancer therapy for gaining insights into tumor development.
    Lv M; Hu W; Zhang S; He L; Hu C; Yang S
    Cancer Lett; 2022 Jul; 539():215716. PubMed ID: 35500825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Targeted protein degradation: elements of PROTAC design.
    Paiva SL; Crews CM
    Curr Opin Chem Biol; 2019 Jun; 50():111-119. PubMed ID: 31004963
    [TBL] [Abstract][Full Text] [Related]  

  • 19. New Frontiers in the Discovery and Development of PROTACs.
    Barghout SH
    Anticancer Agents Med Chem; 2022 Aug; 22(15):2656-2661. PubMed ID: 35418290
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In situ albumin-binding and esterase-specifically cleaved BRD4-degrading PROTAC for targeted cancer therapy.
    Cho H; Jeon SI; Shim MK; Ahn CH; Kim K
    Biomaterials; 2023 Apr; 295():122038. PubMed ID: 36787659
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.